Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChinese Academy of Medical Sciences, Fuwai Hospital

About this trial

The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.

Eligibility criteria

Qualifiers

left ventricular ejection fraction (LVEF)≥50%;

N-terminal pro-b type natriuretic peptide (NT-proBNP)>220pg/ml or b type natriuretic peptide (BNP) >80 pg/ml;

symptoms and syndromes of heart failure;

At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).

Disqualifiers

Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.

Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;

Severe arrhythmia;

Severe primary cardiac valvular disease;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed